Company:  SYNTA PHARMACEUTICALS COR ... (SNTA)
Form Type:  8-K
Filing Date:  7/26/2012 
CIK:  0001157601 
Address:  45 HARTWELL AVE 
City, State, Zip:  LEXINGTON, Massachusetts 02421 
Telephone:  781-274-8200 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.15  
Change: 
-0.04 (-0.96%)  
Trade Time: 
Apr 24  
Market Cap: 
$380.28M
Description of Business
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with cancer and other severe medical conditions. Our lead drug candidate, ganetespib, is a next generation Hsp90 inhibitor in Phase 3 development for non-small cell lung cancer (NSCLC) and in a broad development program including clinical trials for breast cancer, ovarian cancer and acute myeloid leukemia (AML). In addition, we are developing a unique, proprietary platform for enhanced delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates (HDCs). All of our drug candidates were invented by Synta scientists and are fully owned by Synta. In 2013, we made significant progress in expanding the breadth of the ganetespib development program and developing our HDC platform.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 1 BUSINESS AND OPERATIONS
      ITEM 1.01 Entry into a Material Definitive Agreement.
    SECTION 8 OTHER EVENTS
      ITEM 8.01 Other Events.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      ITEM 9.01 Financial Statements and Exhibits.
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 5.1
  EXHIBIT 10.1
  EXHIBIT 99.1
  EXHIBIT 99.2
BROKERAGE PARTNERS